Table 2.
To compare the baseline characteristics of the R/R multiple myeloma patients with or without extramedullary disease.
| With extramedullary disease (n = 7) | Without extramedullary disease (n = 13) | P | |
|---|---|---|---|
| Sex, male | 4 (57.1%) | 8 (61.5%) | >0.99 |
| Age, years | 58 (38-73) | 58 (42-77) | 0.964 |
| KPS >80 | 7 (100%) | 13 (100%) | 0.796 |
| Subtype, %κ light chain | 42.9% | 7.7% | 0.101 |
| ISS stage, I-II:III (n) | 4:7 | 7:6 | 0.444 |
| MM cells in the BM, %, mean (range) | 36.6 (7.8-86.0) | 14.8 (1.8-66.7) | 0.059 |
| Bone lesions | 7 (100%) | 11 (84.6%) | 0.521 |
| Extramedullary MM | 7 (100%) | 0 (0%) | <0.0001 |
| Extramedullary-extraosseous | 6 (85.7%) | 0 (0%) | 0.0002 |
| Extramedullary-bone related | 5 (71.5%) | 0 (0%) | 0.001 |
| High-risk cytogenetic lesions | 3 (42.9%) | 6 (46.2%) | >0.99 |
| Lines of prior therapy, mean (range) | 12 (7-30) | 7 (5-16) | 0.085 |
| 2 (28.6%) | 0 (0%) | 0.111 | |
| Auto-HSCT before BCMA CAR T therapy | 2 (28.6%) | 2 (15.4%) | 0.587 |
Data are presented as n (%) unless otherwise indicated.
ISS, international staging system; MM, multiple myeloma; BM, bone marrow; auto-HSCT, autologous haematopoietic stem cell therapy; CAR, chimeric antigen receptor.
In bold: The only difference between the two groups was the presence of extramedullary disease (P < 0.05).